Cuộc họp Báo cáo Kết quả Kinh doanh Quý 3/2026 của Repligen (RGEN): Doanh thu Kỷ lục và Nâng Dự báo
Cuộc họp công bố kết quả kinh doanh quý 3/2026 của Repligen ghi nhận doanh thu kỷ lục 209 triệu USD, tăng trưởng hữu cơ 12,5%, quá trình tích hợp BioLife và việc nâng dự báo triển vọng cả năm.
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.